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Purpose: The purpose of this study was to assess the safety and early outcomes of the Pipeline device for
large/giant or fusiform aneurysms. 
Materials and Methods: The Pipeline was implanted in a total of 45 patients (mean age, 58 years;
M:F=10:35) with 47 large/giant or fusiform aneurysms. We retrospectively evaluated the character-
istics of the treated aneurysms, the periprocedural events, morbidity and mortality, and the early
outcomes after Pipeline implantation. 
Results: The aneurysms were located in the internal carotid artery (ICA) cavernous segment (n=25), ICA
intradural segment (n=11), vertebrobasilar trunk (n=8), and middle cerebral artery (n=3).
Procedure-related events occurred in 18 cases, consisting of incomplete expansion (n=8), shorten-
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Endovascular coiling is currently a standard treatment
for intracranial aneurysms. However, coiling still has a
higher recurrence rate as compared with clipping,
especially in large or giant aneurysms [1]. Strategies to
overcome this drawback include the development of
various kinds of surface-modif ied coils or liquid
embolic agents [2, 3]. However, such attempts have
failed or have shown limited eff icacy [1-3]. The
Pipeline (Covidien, Irvine, CA, USA) is the first stent-
like endoluminal device that has shown promising
results for the treatment of large/giant, fusiform, or
uncoilable complex aneurysms [4-10]. However, the
Pipeline was not launched in Korea until November
2014. 
In this study, we report the periprocedural complica-
tions, morbidity and mortality, and early clinical and
angiographic outcomes after the implantation of the
Pipeline for unruptured large/giant ( 15 mm in size)
or fusiform aneurysms from an early multicenter
experience in Korea. 
MATERIALS AND METHODS
Patients
The Pipeline was implanted in 45 patients with 47
unruptured large/giant or fusiform aneurysms in 12
hospitals in Korea between November 2012 and March
2015. Except for exceptional uses for proctorship
purposes, the majority of the Pipeline implants were
performed after November 2014, when reimbursement
for the Pipeline was allowed. The procedure was
conducted with the assistance of the proctors, who had
worked in at least 20 Pipeline implantations, until the
operator completed at least 5 cases. By the end of the
study period, one operator completed 10 cases, two
operators completed 5-9 cases, seven operators
completed 2-4 cases, and five operators completed 1
case. 
Pipeline implantation
All procedures were performed under general
anesthesia. All patients received dual antiplatelet
premedication (aspirin 100-325 mg and clopidogrel
300 mg) for at least f ive days. For all patients,
antiplatelet resistance was tested before treatment, and
antiplatelet medication was adjusted as recommended
by proctors in cases where drug resistance was
detected. For large or giant aneurysms with mass effect
or with a possible increased risk of delayed rupture,
steroid loading was given orally and tapered as
previously described [9]. 
After a 6F shuttle (Cook) or a 6F guiding catheter
(Envoy, Coddman Neurovascular, CA, USA) was
placed in the relevant cervical carotid or vertebral
artery, a 0.027-inch Marksman catheter (Covidien,
Irvine, CA, USA) was advanced over a 0.014-inch
guidewire across the aneurysm neck. In cases where
catheter navigation across the aneurysm neck into a
parent artery branch distal to the aneurysm was
difficult, an exchange technique was applied using a
0.010-inch microcatheter and a 300-cm length
exchangeable wire (Transend, Stryker). Next, a Pipeline
that matched the largest diameter of the parent artery
was introduced and implanted so that it was fully
covering the aneurysm neck. 
Outcome measure
We retrospectively evaluated the presenting
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ing-migration (n=5), transient occlusion of a jailed branch (n=3), and in-stent thrombosis (n=2).
Treatment-related morbidity occurred in two patients, but without mortality. Both patients had
modified Rankin scale (mRS) scores of 2, but had an improved mRS score of 0 at 1-month follow-up.
Of the 19 patients presenting with mass effect, 16 improved but three showed no changes in their
presenting symptoms. All patients had excellent outcomes (mRS, 0 or 1) during the follow-up peri-
od (median, 6 months; range, 2-30 months). Vascular imaging follow-up (n=31, 65.9%; median, 3
months, range, 1-25 months) showed complete or near occlusion of the aneurysm in 24 patients
(77.4%) and decreased sac size in seven patients (22.6%). 
Conclusion: In this initial multicenter study in Korea, the Pipeline seemed to be safe and effective for
large/giant or fusiform aneurysms. However, a learning period may be required to alleviate device-
related events. 
Key Words: Pipeline; Flow diverter; Aneurysm
symptoms, aneurysm characteristics (type, location,
dome and neck sizes, and the presence of an intra-
saccular thrombus), the periprocedural events,
treatment-related morbidity and mortality, and early
clinical and radiological outcomes after Pipeline
implantation. Treatment-related morbidity was defined
as any neurological deterioration unrelated to preexist-
ing cranial nerve signs due to the aneurysm’s mass
effect. Clinical outcome was evaluated according to the
modif ied Rankin scale score (mRS) where mRS 0
indicates no symptoms and mRS 6 indicates death. The
aneurysm’s occlusion at follow-up vascular imaging
(catheter angiography or CT angiography) was catego-
rized as complete or near-complete occlusion
(aneurysm occlusion > 90%), decreased sac size (30%
< aneurysm occlusion < 90%), or no change (aneurysm
occlusion < 30%). In addition, the change in the size of
the treated aneurysms, including the thrombosed
portion, was assessed in cross-sectional follow-up CT
or MR images. The institutional review boards of the
participating institutions approved this retrospective
study and waived patient informed consent based on
the study design. 
RESULTS
The characteristics of the patients and aneurysms are
summarized in Table 1. In two cases of giant intradural
aneurysms, several coils were inserted into the sac to
more rapidly induce thrombosis. In one case, a stent
graft (Jostent graft, Abbott Vascular Devices) was
adjunctively used to anchor the Pipeline to the proximal
portion of the parent artery because the diameter of the
proximal portion was 5.5 mm, while the largest
Pipeline has a size of 5 mm. 
The device-related events and periprocedural compli-
cations are summarized in Table 2. Specif ically,
incomplete expansion of Pipeline was detected in 13
cases, of which 11 eventually required balloon
angioplasty for full expansion of the Pipeline. In-stent
thrombosis occurred in two cases, which caused side
branch occlusion but completely resolved with intraar-
terial Glycoprotein IIb/IIIa inhibitor (Tirofiban, 05-1.0
mg) infusion. Another case showed a sluggish flow into
the MCA branch but was not treated. The patient had a
subclinical infarction in the MCA territory. 
Treatment-related morbidity occurred in two patients
(4.4%) but without mortality. One patient had a minor
embolic infarction in the MCA territory. The other
patient had an anterior thalamoperforator infarction due
to the retained delivery wire of Pipeline in the posterior
communicating artery. Both patients had modif ied
Rankin scale (mRS) scores of 2 after the treatment but
had an improved mRS score of 0 at 1-month follow-up. 
Of the 18 patients presenting with cranial nerve
defects, 15 showed improvements in their presenting
symptoms but three patients showed no change. In the
15 patients with improvement, presenting symptoms
were initially aggravated 1-3 days posttreatment but
improved over 3-8 weeks after Pipeline implantation.
The only patient with evidence of brainstem compres-
sion also slowly improved in presenting symptoms over
three weeks after treatment. All patients had excellent
outcomes (mRS, 0 or 1) during the follow-up period
with a median of six months (range, 2-30 months).
Vascular imaging follow-up with catheter or CT
angiography was available in 31 aneurysms (65.9%) for
a median of three months (range, 1-25 months).
Vascular imaging follow-up showed complete or near-
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Table 1. The Characteristics of Patients and Aneurysms
Number of patients (aneurysms) 45 (47)
Age 58 years (35 - 80 years) 
Male: Female 10:35
Presentation (n=45)
Incidental 13 (28.9%)
Cranial nerve palsy headache 18 (40.0%)
TIA/stroke headache 4 (8.9%)
Chronic headache 6 (13.3%)
Recurrent aneurysm 2 (4.4%)*
Stem compression 1 (2.2%)
Seizure 1 (2.2%)
Aneurysm location (n=47)
Internal carotid artery, cavernous segment 25 (53.2%)
Internal carotid artery, intradural segment 11 (23.4%)
Vertebrobasilar artery trunk 8 (14.9%)
Middle cerebral artery 3 (6.4%)
Aneurysm shape (n=47)
Saccular 37 (78.7%)
Fusiform 10 (21.3%)
Sac size, mean SD 20.8 6.1 mm
Neck size, mean SD 11.9 4.7 mm
Intra-aneurysmal thrombus 24 (51.1%)
*One aneurysm was treated with coiling and the other with
clipping.
complete occlusion in 24 patients (77.4%) and
decreased sac size in seven patients (22.6%).
Asymptomatic in-stent stenosis was detected in one
case at the 6-month follow-up angiography, which
markedly improved at the 12-month follow-up angiog-
raphy (Fig. 1). Cross-sectional imaging follow-up at 
1 month with CT or MR was available in 35 aneurysms
(74.5%) for a median of three months (range, 1-25
months). The treated aneurysms, including the
thrombosed portions, disappeared in f ive patients
(14.3%) (Fig. 2), showed a decreased size in 24 patients
(68.6%), and showed no change in six patients (17.1%).
In the six cases without changes in the sizes of the
thrombosed aneurysm, the latest follow-up cross-
sectional images were obtained one to three months
after Pipeline implantation. The vascular and cross-
sectional imaging results on follow-up are detailed in
Table 3.
DISCUSSION
In the treatment of cerebral aneurysms, coiling is
known to have a higher recurrence rate than clipping,
especially in large or giant aneurysms [1]. Although a
variety of strategies have been attempted to overcome
this drawback, they have failed or have shown limited
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Table 2. Procedural Events and Treatment-Related Morbidity
Number of Pipelines used (n=47), mean 1.2 
N=1 37 (78.7%)
N=2 9 (19.1%)
N=3 1 (2.1%)
Adjunctive device (n=47) 3 (6.4%)
Coil 2 (4.3%)
Stent graft 1 (2.1%)
Ballooning required post-Pipeline 11 (23.4%)
Device-related events (n=47) 18 (38.3%)
Incomplete expansion 13 (27.6%)
Shortening-migration 5 (10.6%)
In-stent thrombosis 2 (4.3%): resolution with Glycoprotein IIb/IIIa inhibitor in both cases —> no symptoms
Sluggish or occlusion of jailed branch 3 (6.4%): 2 cases were associated with in-stent thrombosis —> resolved after IIb/IIIa 
inhibitor in both cases —> no symptoms
no treatment in1 case —> subclinical infarction
Treatment-related morbidity 2 (4.4%), mRS 2 due to ischemic stroke in both cases —> 
mRS 0 at 1 month in both cases
Treatment-related mortality 0
Table 3. Follow-up Imaging Outcomes after Pipeline Implantation
Follow-up vascular imaging evaluated (n=47) 29 (64.7%)
Complete or near-complete occlusion (n=22, 75.9%) 1-3 months (n=14), 6 months (n=4), 12-24 months  (n=4)
Decreased sac size (n=7, 24.1%) 1-3 months (n=7)
Follow-up cross-sectional imaging evaluated (n=47) 35 (74.5%)*
Aneurysm disappearance (n=5, 14.3%) 6 month (n=4), 12-24 months (n=1)
Decreased size (n=24, 68.6%) 1-3 month (n=9), 6 months (n=11), 12-24 months (n=4)
No change (n=6, 17.1%) 1-3 month (n=6)
*Evaluation of the change in the treated aneurysm size, including the thrombosed portion on follow-up CT or MR.
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efficacy [1-3]. Furthermore, even with stent assistance,
coiling is very difficult to perform and especially risky
in blister-like, dissecting, or fusiform aneurysms [11-
13]. The use of single or multiple overlapping stents
has helped, to a certain extent, prevent recurrence and
treat uncoilable aneurysms [1, 11-19]. It has also been
suggested that overlapping stents could further improve
aneurysm healing due to the reinforced flow-diverting
effects of increasing the metal density covering the
aneurysm neck [16-19]. 
The Pipeline, a stent-like endoluminal device with
high metal density, was invented for the treatment of
aneurysms by flow diversion without coiling, and has
been shown to have promising results for the durable
occlusion of large or giant aneurysms [4-10]. After the
introduction of the Pipeline, other flow-diverting
devices have been invented and applied to the treatment
of aneurysms [19-22]. According to one recent meta-
analysis, the complete aneurysmal occlusion rate was
76% overall and 80% for small aneurysms, 74% for
large aneurysms, and 76% for giant aneurysms. The
procedure-related morbidity and mortality rates were
5% and 4%, respectively. The rate of postoperative
subarachnoid hemorrhage was 3% and the rate of
intraparenchymal hemorrhage was 3%. The perforator
infarction rate was 3%, with significantly lower odds of
perforator infarction among patients with aneurysms of
the anterior circulation as compared with those of the
posterior circulation [23]. Although the risks of
procedure-related morbidity and mortality are not
negligible, the treatment of intracranial aneurysms with
flow-diverters is feasible and effective with high
A B C
Fig. 1. A 51-year-old woman with bilateral distal internal carotid artery aneurysms.
A, B. Frontal projection and 3-D reconstruction images show a large aneurysm at the intradural para-ophthalmic segment of the right
internal carotid artery. The asterisk indicates a coil-embolized aneurysm at the left distal internal carotid artery. The asterisk indicates the
coil embolized aneurysm of left internal carotid artery. C. Angiogram after Pipeline implantation shows markedly decreased flow into the
aneurysm sac. D. A flat-panel CT image shows incomplete expansion of the distal portion of the Pipeline resulting in poor wall apposition
(arrow). E. After ballooning for wall apposition of the Pipeline, the distal end (arrowhead) of the pipeline was partially herniated into the
aneurysm sac, resulting in alleviation of the flow diversion effect. F. A spot image after the second Pipeline implantation in a telescopic
manner. Note the waist of the second Pipeline at the distal end (arrowhead) of the first Pipeline, which partially herniated into the sac. 
Continued 
D E F
complete occlusion rates, especially considering the
fact that flow-diverters have mainly been used for the
treatment of aneurysms that are large/giant in size,
uncoilable, or have failed prior treatment [23]. 
In this study, the Pipeline, the f irst flow diverter
introduced in Korea, showed an approximately 77%
complete or near-complete occlusion rate for
large/giant or fusiform aneurysms in this multicenter
study, although the median follow-up duration was only
three months. In the study duration, there have been no
cases of intracranial hemorrhage after Pipeline implan-
tation, either related or unrelated to the treated
aneurysms. The treatment-related morbidity was 4.4%
(n=2, mRS, 2 in both cases), without any cases of
disabling morbidity or mortality. Several factors might
have affected these morbidity and mortality rates,
which are lower than those reported in the literature.
For one, operators could prepare for the known compli-
cations of Pipeline implantation by reading previous
reports. For example, steroids were given for cases
involving giant aneurysms, which have a high risk of
delayed aneurysm rupture or an aggravation of the
mass effect, as previously described [9]. According to
previous reports, the risk of rupture in Pipeline-treated
aneurysms increases with aneurysm size [9]. In
addition, antiplatelet premedication was modif ied
according to tests for drug resistance, as recommended
by the proctors. Finally, in almost all of the cases, the
procedure was performed with assistance from experi-
enced proctors. These proctors could decrease
treatment-related morbidity by advising operators on
how to avoid and manage device-related events.
Despite these factors that may have reduced morbidity
and mortality, the considerable incidence of device-
related events is notable. The most common device-
related event was associated with deployment difficul-
ties, such as incomplete expansion and shortening-
migration, especially in tortuous parent arteries, which
required ballooning post-Pipeline and even additional
Pipeline implantations in a few cases (Fig. 1). This is
likely because the Pipeline is mainly composed of a
Co-Cr alloy strand that has less self-expanding force
than nitinol alloy. Another explanation is that the
technique for Pipeline implantation is quite different
Neurointervention 11, March 2016 15
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Fig. 1. G. After using a balloon for the apposition of the second Pipeline, the aneurysm
sac was no longer visualized. The arrowhead indicates the distal end partially herniated
into the sac. H. A flat-panel CT image showing that a mild degree of the waist of the
second pipeline still remained at the end of the first pipeline. Note the twisted struts
(arrows) at the waist point. I. The 6-month follow-up angiogram shows a severe degree of
in-stent stenosis, even though the patient remained asymptomatic. The left anterior
cerebral artery was supplied via the anterior communicating artery from the left internal
carotid artery (not shown). J. The 12-month follow-up angiogram shows improvement of
the in-stent stenosis. 
from the technique currently used with neurovascular
stents that are made by the laser-cutting of a nitinol
tube. The operators tended to have little or no experi-
ence in the use of the Pipeline. 
This study has several limitations. The number of
included cases was relatively small. In addition, follow-
up was not completed in all cases and the follow-up
period was not long enough. We also did not compare
the Pipeline with stent-assisted coiling in the treatment
of large or giant aneurysms. Despite these limitations,
this report was intended to offer early results from an
initial multicenter experience with the Pipeline device.
The results of this report can offer future users of flow
diverters in Korea with helpful information for improv-
ing outcomes. Future studies on flow-diverters should
focus on aneurysms that are 10 mm in size, ruptured
blood blister-like or dissecting, recurrent, and uncoil-
able.
CONCLUSIONS
In this initial multicenter experience in Korea, the
Pipeline seemed to be safe and effective for large/giant
or fusiform aneurysm. However, a learning period may
be required to reduce device-related events, which can
potentially lead to treatment-related morbidity. 
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Fig. 2. A 67-year-old woman presenting with third and sixth cranial nerve palsies and a recently aggravated intractable headache.
A. The coronal MIP reconstruction image of the CT angiogram shows a giant aneurysm at the left internal carotid artery, cavernous
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B. A lateral projection angiogram shows a giant aneurysm at the left internal carotid, cavernous segment. C. Final control angiogram
after the pipeline implantation shows marked flow diversion with contrast material stagnation in the aneurysm sac. D. A source image of
the 3-month follow-up CT angiogram shows that the aneurysm was completely thrombosed. The bulging contour of the left cavernous
sinus (arrowheads) remained due to the thrombosed aneurysm. E, F. The source (E) and coronal MIP reconstruction (F) images of the
6-month follow-up CT angiogram show that the thrombosed aneurysm disappeared and that the left internal carotid artery was patent.
Note that the left distal internal carotid and middle cerebral arteries were normal-positioned without tenting (arrow). 
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